To control treatment pathways of transplant patients across healthcare sectors, a profound knowledge of the underlying cost structure is necessary. The aim of this study was to analyze the resource utilization of patients undergoing liver transplantation. Data on resource utilization for 182 livertransplanted patients was investigated retrospectively. The observational period started with the entry on the waiting list and ended up to 3 years after transplantation. Median treatment cost was 144 424€. During waiting time, median costs amounted to 9466€; 72% of costs were attributed to inpatient care, 3% to outpatient care, and 26% to pharmaceuticals. During the first year after transplantation, median costs of 105 566€ were calculated; 83% were allocated for inpatient and 1% outpatient care, 14% for drugs, and 1% for rehabilitative care. During follow-up after the first year of transplantation, median costs amounted to 20 115€; 75% of these were caused by pharmaceuticals, 21% by inpatient, 4% by outpatient, and <1% by rehabilitative services. Subgroup analyses (e.g., for labMELD scores) were done. Costs incurred by inpatient care and pharmaceuticals are the dominating cost factors. These findings encourage a debate on challenges and improvements for cost-efficient clinical management between different healthcare sectors.
SUMMARY
To control treatment pathways of transplant patients across healthcare sectors, a profound knowledge of the underlying cost structure is necessary. The aim of this study was to analyze the resource utilization of patients undergoing liver transplantation. Data on resource utilization for 182 livertransplanted patients was investigated retrospectively. The observational period started with the entry on the waiting list and ended up to 3 years after transplantation. Median treatment cost was 144 424€. During waiting time, median costs amounted to 9466€; 72% of costs were attributed to inpatient care, 3% to outpatient care, and 26% to pharmaceuticals. During the first year after transplantation, median costs of 105 566€ were calculated; 83% were allocated for inpatient and 1% outpatient care, 14% for drugs, and 1% for rehabilitative care. During follow-up after the first year of transplantation, median costs amounted to 20 115€; 75% of these were caused by pharmaceuticals, 21% by inpatient, 4% by outpatient, and <1% by rehabilitative services. Subgroup analyses (e.g., for labMELD scores) were done. Costs incurred by inpatient care and pharmaceuticals are the dominating cost factors. These findings encourage a debate on challenges and improvements for cost-efficient clinical management between different healthcare sectors.
Introduction
Liver transplantation (LTx) is known to be a very resource-intensive therapy. Patients need comprehensive diagnostic evaluation by a multidisciplinary team. Medical care necessitates the availability of highly qualified staff at every daytime. After transplantation (Tx), patients need intensive care treatment while lifelong immunosuppression is mandatory [1] [2] [3] . Due to the MELD-based allocation system, most of the patients are transplanted with a MELD score higher than 30, which underlines the necessary medical care while patients are on the waiting list (Figs 1 and 2) [4] .
Various stakeholders and institutions across different healthcare sectors are involved in the treatment process (Figs 3 and 4). Within this process, different forms of compensation exist though (Fig. 3) [5] . General practitioners (GP) and specialists are reimbursed within the Statutory Health Insurance (SHI) scheme (Einheitlicher Bewertungsmaßstab, EBM) [6] . However, the inpatient pre-to postoperative activities are compensated by the German diagnosis-related groups system (G-DRG) [7] . By contrast to that, the outpatient transplant clinic remunerates on the EBM scheme wherefore a certain authorization of the physicians' association (Kassen€ arztliche Vereinigung, KV) is required [8] .
So far, there is only scarce information available on total treatment costs of liver transplantation. Existing German studies give only an insight into inpatient costs, without providing information on medical services prior to and after the inpatient treatment [1, 3, [9] [10] [11] [12] . In relation to the overall costs, these are of particular interest to understand the complete picture of the healthcare cost structure in liver transplantation.
The aim of this study is to determine inpatient and outpatient costs for LTx including costs for rehabilitation and drugs with a focus on identifying the main cost drivers. The underlying hypothesis of this study is that a more detailed insight into cross-sectoral cost structures of LTx in Germany is necessary to manage, control and improve treatment pathways across healthcare sector interfaces. A profound knowledge of the underlying cost structure is necessary to understand possible incentives as well as the potential for conflict and process optimization to ensure cost-efficient clinical management. We believe that the findings of this study are of general relevance as they indicate quantitative costs that are incurred in different healthcare sectors and treatment phases of liver transplant patients. Figure 1 Percentage of deceased donor liver transplants, by recipient urgency at transplant [4] . Due to the MELD-based allocation system, most of the patients are transplanted with a MELD score higher than 30, which underlines the necessary medical care while patients are on the waiting list. The number of deceased donor transplants is still lower than the number of patients on the waiting list, even though the number of deceased donors raises slightly [4] . 
Patients and methods
This is a single-center retrospective cohort study from a transplant center in Germany. The Ethics Committee at Hannover Medical School has approved this study and stated that an observational retrospective study with ongoing data collection, according to the Professional Code of the German Medical Association (article B.III. § 15.1), neither informed consent nor approval of the ethics committee was needed.
Inclusion and exclusion criteria
Included were liver recipients (≥18 years) who were transplanted between 01.01.2010 and 31.12.2013 (n = 212). Patients with combined transplants were excluded (n = 11), while patients who were transplanted with another organ earlier or later were included into analysis. As this study was conducted from the perspective of the SHI System, 18 patients who were not covered by this system were excluded from analysis due to a lack of available data for analysis. One additional patient had to be excluded due to loss to follow-up. Data of 182 patients were finally available for analysis.
Observational period
The observational period starts with the entry on the waiting list and ends 3 years after transplantation, with the date of death or on the 31.12.2015. In Germany, it is obligatory to report survival rates up to 3 years after transplantation for quality assurance purposes, so we used this to justify the end of our observational period [13, 14] . The observational period was segregated into three time frames 1 T1 starts with the entry on the waiting list until transplantation; 2 T2 comprises the first year after transplantation; 3 T3 starts after the first after transplantation year until the end of follow-up.
If a patient had a subsequent liver retransplant, we used the date of the first transplant as the reference for analyzed time frames. For each time frame, we collected the services a patient received at the following healthcare sectors (Table 1) 
Database and cost calculation
The clinical and demographic data were retrieved from patient records. Besides the sociodemographic data, we extracted the allocation MELD scores, the type of transplanted graft (split liver, partial, reduced size, or full size graft), living-related versus postmortem donation after brain death, the indication for transplantation, and whether the patient received one or more transplants during follow-up.
Data on prescribed drugs, hospitalizations, services in the outpatient transplant clinics and days of rehabilitation were systematically extracted using several clinical information systems and files. Prescribed drugs were classified into immunosuppressants and other pharmaceuticals.
Outpatient clinical care included the services a patient received at a doctor visit in terms of a scheduled fee position which was derived from the German Doctors' Fee Scale [15] .
Costs of any drug prescribed at the outpatient service were taken from the German Medical Prescriptions Record [16] or if not applicable, from the database of the Lauer-Taxe (German reference work for prices of pharmaceuticals) [17] . These were derived in relation to the prescribed dose and number of days until the next date of visit. If no further date of visit was available, we used the calculated average days between visits. Hospitalization costs were calculated using the G-DRG system [18] . The G-DRG-codes A01A, A01B, A01C, A18Z (see Table 2 for definitions) are relevant for reimbursement for LTx and were available for all analyzed cases. Discount and surcharges depending on the length of hospitalization were applied.
The prices for the days of rehabilitation were taken from the report of the Federation of German Pension Insurance Institutions. In 2013, the costs for medical rehabilitation for the direct treatment of a physical illness were amounted to 2685€ for a single patient [19] . The average duration of a stay in a rehabilitation clinic was 23.5 days. So 1 day of rehabilitation amounted to 114.26€. All costs which were provided through the data (Table 1) refer to the year in which they were accounted. All other costs refer to the price year 2013, as this was the year of the data cut.
Statistical analyses
Statistical analyses were carried out with JMP â PRO 11.2.0 (SAS Institute Inc., Cary, NC, USA). The twosided Student's t-test was used for nominal dependent and analysis of variance (ANOVA) for continuous-dependent outcome parameters. Univariable linear regression was used where appropriate. The level of significance was defined as P < 0.05.
Results

Patient characteristics
Among 182 analyzed patients, the median pre-transplant labMELD score was 16.5. The most frequent diagnosis leading to transplantation was a hepatocellular carcinoma (HCC) (23.6%), followed by alcoholic cirrhosis of liver (13.2%). Sixteen patients were retransplanted once, while one patient was retransplanted twice. The mean age was 49.3 years, and 54.4% of patients were male; 94.5% of patients were transplanted with a full size organ and there were no living donations (Table 3) . Table 2 . Definitions of most frequent G-DRG-codes.
DRG-code Definition
A01A
Liver transplantation with mechanical ventilation >179 h A01B Liver transplantation with mechanical ventilation >59 and <180 h or acute graft rejection or combined kidney transplantation A01C
Liver transplantation with mechanical ventilation >59 h without graft rejection, without combined kidney transplantation A18Z
Mechanical ventilation >999 h and transplantation of the liver, lung, heart, and bone marrow or stem cell transfusion A60C
Failure and rejection of a transplanted organ, more than 1 day of an inpatient stay, without removal of a transplanted organ, without complex operation room procedure, without very severe CC, age >15 years A60D
Failure and rejection of a transplanted organ, 1 day of an inpatient stay A64Z Inpatient evaluation for liver or kidney-pancreas transplantation H41A
Complex therapeutic ERCP with very severe CC or photodynamic therapy H41B
Complex therapeutic ERCP with severe CC, without photodynamic therapy or age <16 years or complex intervention H41C
Complex therapeutic ERCP without very severe or severe CC, without photodynamic therapy, age >15 years, without complex intervention, or other ERCP H60Z
Cirrhosis of the liver and certain non-infectious hepatitis with very severe CC H61B
Malignant neoplasm of the hepatobiliary system and pancreas, 1 day of an inpatient stay or without complex diagnosis or without very severe CC, without portal vein thrombosis H63A
Liver disease other than malignant neoplasm, cirrhosis of the liver, and certain non-infectious hepatitis, more than 1 day of an inpatient stay, complex diagnosis and very severe or severe CC, or complex diagnosis or very severe or severe CC, age <1 year H64Z
Disorders of gallbladder and biliary tract Z64B
Other factors influencing health status and treatment after an completed treatment without radioiodine diagnostic, with a certain occasion for contact Z64C
Other factors influencing health status and treatment after an completed treatment without radioiodine diagnostic, without a certain occasion for contact
The median length of the observational period was 1183 days (range: 6-4347 days). The median waiting time (T1) for transplantation was 227 days (range: 2-3251 days). In T2, 50% of the patients spend up to 365 days (range: 1-365 days) and in T3 up to 731 days (range: 0-731 days). Thirty-five patients died after transplantation (19.2%). Of these deceased patients, 29 died during T2 (82.9%) and six during T3 (17.1%). After the observational period, four more patients died without their death influencing the results of the cost calculations in this study.
Costs per time frame
Complete observational period
The total amount of costs for all patients was 36 118 547€, with median costs that amounted to 144 424€ (Table 4 , Fig. 5 ). The duration of the observational period did not have a significant influence on overall costs (P = 0.20, ANOVA).
Females incurred lower median treatment costs (135 010€) as compared to males (154 923€) without reaching statistical significance (P = 0.61, two-sided t-test).
The labMELD score at the time of allocation had no significant influence on overall treatment costs (P = 0.11, ANOVA).
The age of the recipient at the time of transplantation had a significant influence on overall costs (P = 0.02, ANOVA) (Fig. 6 ). The increase in median overall costs was calculated to increase by 2155€ for every year the organ recipients were 1 year older at the time of transplant (Fig. 6) .
Patients with subsequent retransplants incurred significantly higher overall costs: 241 283€ (range: 128 795-507 586€) compared to 139 434€ (range: 16 162-887 418€) for patients without subsequent retransplants (P = 0.02, two-sided t-test). Table 3 . Shown are the patient characteristics. Binary data given in frequency (n) and percent (%), and continuous data described with mean, standard deviation (SD), median and range. With a longer time on the waiting list, treatment costs rose significantly (P < 0.01, ANOVA). Total costs for all patients amounted to 2 402 164€, with a median of 9466€. The most cost-intensive part was caused by inpatient stays with a total sum for all patients of 1 725 939€ (72%) with the median of costs at 6294€. The outpatient service costs summed up for all patients to 61 538€ (3%) with median costs at 130€. All patients received medications amounting to 614 686€ (26%) with a median of costs at 175€ (Table 4 ).
The labMELD score at the time of donor organ allocation had a significant influence on overall treatment costs in T1. Patients with a lower labMELD score incurred higher costs as compared to patients with a higher lab-MELD score (P = 0.01, ANOVA). Patients with a higher labMELD score had significantly shorter waiting times (P < 0.001, ANOVA) and therefore caused lower costs.
Primary sclerosing cholangitis (PSC) leading to transplantation was accountable for the highest median costs in T1 (22 771€), followed by patients with a subsequent transplantation (21 461€ ) and the indication of HCC (13 521€) ( Table 5) .
Post-transplant year (T2)
During the second time frame, overall costs of 26 641 777€ were accrued (median costs: 105 566€). For inpatient care, the total amount was 22 232 459€ (83%) with median costs at 75 531€. The outpatient service did amount to 266 560€ in total (1%) (median: 1484€). Above that, for all patients together 1 449 496€ (5%) were spent on immunosuppressants and 2 524 043€ (9%) on other medications (median: 6576€ and 5356€, respectively); 36.8% of the patients had an inpatient rehabilitation after transplantation. In total, this service amounted to 169 219€, with an average value of 930€ (median: 0€; most of the patients did not receive a rehabilitation program and were thus taken into account with 0€) (Table 4) .
In contrast to T1, patients with higher labMELD scores incurred higher costs as compared to patients with lower labMELD scores during T2 (P = 0.01, ANOVA) (Fig. 7) . Patients who died during follow-up (19.2%) incurred significantly higher costs (median: 159 321€, range: 10 054-495 351€) as compared to surviving patients (80.8%) (median: 91 057€, range: 29 103-612 605€) (P = 0.01, two-sided t-test) (Fig. 8) . This is due to the fact that deceased patients typically required intensive medical care before they die. The majority (82.9%) died after a median of 88 days after transplantation (mean: 132 days).
The indication which led to the highest median costs during T2 was cryptogenic cirrhosis (159 298€). Patients with viral cirrhosis were accountable for the second highest costs (137 800€), while HCC led to median costs of 28 464€ (Table 5) .
Follow-up after the transplantation year (T3)
A longer duration of T3 was associated with significantly higher treatment costs (P = 0.01, ANOVA). A total amount of 7 074 607€ was accrued, with a median of 20 115€; 46% of this sum was caused by costs for prescribed drugs (3 226 439€), and 29% of total costs for all patients was caused by expenses for immunosuppressive drugs (2 025 726€). For inpatient treatments, a Figure 7 Overall costs per time frames T1-T3 and labMELD. The graphs show the results of linear regression with a 95% CI (shadowed areas). The analysis illustrates the influence of the labMELD score of the overall costs during the waiting time (T1) (P = 0.01), the transplant year (T2) (P = 0.01), and 2 years after T2 (T3) (P = 0.49).
Figure 8
Overall costs and death during waiting time (T1), the transplant year (T2), and 2 years after T2 (T3). The overall costs are presented as boxplots. The difference of costs incurred by deceased versus surviving patients was significantly higher for deceased patients in T2 (P = 0.01) while costs were significantly lower for deceased patients in T3 (P = 0.01). This difference was not significant in T1 (P = 0.97). As a consequence of the inclusion criteria for this study, no deaths were reported during T1 (time on the waiting list for transplantation).
total of 1 513 955€ (21%) was incurred. The costs for the outpatient service in this period amounted to 306 087€ (4%) ( Table 4) .
During T3, the pre-transplant labMELD score had no significant influence on the overall costs (P = 0.49, two-sided t-test) (Fig. 7) . Patients who died during followup incurred significantly lower treatment costs compared to surviving patients (P = 0.01, two-sided t-test) going along with a shorter follow-up time in T3 for deceased patients (median: 0 days, range: 0-554; mean: 32 days) (Fig. 8) .
Patients with Budd-Chiari syndrome as underlying disease incurred the highest median costs during T3 (31 655€), while viral cirrhosis led to median costs of 29 222€ and HCC to 28 464€ (Table 5 ).
Costs per sector
Inpatient care
The most frequent (≥5%) G-DRG-codes reflecting hospitalization treatment costs during each time frame T1-T3 are represented in Table 6 .
The labMELD score at the time of donor organ allocation had a significant influence on inpatient overall costs. Higher labMELD scores incurred significantly higher costs (P = 0.01, ANOVA) (Fig. 9) .
Patients with cryptogenic cirrhosis as underlying disease incurred the highest median costs at 157 380€ during inpatient care, followed by those patients with a subsequent liver retransplantation (143 597€) and an alcoholic cirrhosis (131 913€) ( Table 5 ).
Waiting time (T1). During T1, clinical evaluation for transplantation (G-DRG: A64Z) accounted for the highest costs, with a total amount of 544 610€. A further costintensive factor during inpatient stay was complex endoscopic retrograde cholangiopancreatography (ERCP) amounting to 274 916€. Hereby, PSC was the most frequent indication (45%) leading to ERCP. The indications viral cirrhosis (41%), HCC (23%) and PSC, cryptogenic cirrhosis, and alcoholic cirrhosis accounted together for the third biggest amount of costs (90 036€ in total) and are presented through the G-DRG-code H63A (Table 6) .
Lower allocation labMELD scores were associated with significantly higher inpatient costs in T1 (P = 0.03, ANOVA), which is due to usually longer treatment durations.
Post-transplant year (T2). The G-DRG-codes which account for the biggest cost part with a total sum of 20 594 702€ are shown in Figure 10 . The main indications for the most expensive G-DRG-code (A18Z) were HCC (27%) and alcoholic cirrhosis (27%). For the second most cost-intensive code A01A, HCC (20%) and an acute and subacute liver failure (20%) were the main indications. HCC (24%) and viral cirrhosis led to the third most costintensive code A01B, while HCC (25%) and a PSC (15%) were most accountable for the G-DRG-code A01C.
After the costs for the transplant procedure, the most cost-intensive codes were for different ERCP interventions, representing a total amount of 299 787€. Hereby, liver malignancy was the main diagnosis group (45%) leading to ERCP. Graft failure or rejection led to the third most cost-intensive code (in total 129 483€) ( Table 6 ).
During T2 higher allocation, labMELD scores incurred significantly higher inpatient costs (P < 0.01, ANOVA).
Follow-up after the first post-transplant year (T3). The majority of costs for hospital treatments were incurred through ERCP interventions, which were mainly (41%) associated with liver malignancy (total costs: 267 140€). Treatment for graft failure and rejection accounted for the second most cost-intensive treatments in T3 (89 053€), while other factors represented the rest (44 970€) ( Table 6 ).
The allocation labMELD scores had no significant influence (P = 0.73, ANOVA) on inpatient costs during the third time frame (T3).
Outpatient care
In contrast to inpatient care, lower allocation labMELD scores had a significant influence on higher outpatient costs (P = 0.05, ANOVA) (Fig. 9) . Split by different investigated time frames T1, T2, and T3, this relationship was statistical significant during waiting time (T1) (P < 0.01, ANOVA) but not during T2 and T3 (P = 0.14; P = 0.39, ANOVA).
Patients with Budd-Chiari syndrome as underlyling disease were accountable for the highest median costs during outpatient care (5729€), followed by patients with PSC (4447€) and cryptogenic cirrhosis (4173€) ( Table 5) .
During outpatient care, the total costs for immunosuppression after transplantation in T2 and T3 were 3 475 222€, with a median of 16 838€ (range: 0-66 704€). Table 7 summarizes the costs for the most commonly used immunosuppressive drugs.
About 1500 different medications other than immunosuppression were analyzed. Some patients received very expensive medications for a long duration due to the nature of their underlying chronic disease, such as a viral hepatitis B or C ( Table 5 ). The ten most cost-intensive pharmaceuticals before and after transplantation administered during outpatient treatment are listed in Table 8 . Costs for these drugs ranged between 2000€ and 16 000€ before transplantation and from 12 000€ to 125 000€ after transplantation in total per patient (rounded for thousands of €).
Rehabilitation
After transplantation, 67 patients (36.8%) had an inpatient stay in a rehabilitation clinic. Almost all of these hospitalizations were within T2; only one patient had inpatient rehabilitation in T3. The mean number of days spent in a rehabilitation clinic was 24, whereby the shortest stay was 5 days and the longest 60. The total cost for rehabilitation was 171 619€ with an average cost of 943€ (95% CI: 739-1147€).
Discussion
The results of this study clearly highlight the dominating role of costs incurred by inpatient care for the treatment Figure 9 Inpatient and outpatient overall costs. The graphs show the results of linear regression analysis with a 95% CI (shadowed areas). The analysis illustrates the influence of the labMELD score of the overall costs for the inpatient stay (P = 0.01) and the outpatient services (P = 0.05) during the whole observational period. of liver transplant candidates and recipients. These services constantly dominate each time frame (T1-T3) and are responsible for 71% of total costs. It is striking that pre-and post-transplant outpatient medical services (2%) and post-transplant rehabilitation costs (<1%) incur a comparatively small part of the total costs. Hence, process improvement of inpatient treatment is most likely enabling optimization treatment costs.
This study further highlights the meaningful proportion of total costs for necessary lifelong medication, especially during T2 (14%) and T3 (28%) ( Table 4) . In this context, some underlying chronic diseases leading to LTx such as viral cirrhosis require highly expensive drugs over prolonged periods of time (Table 5) . Cost optimization for pharmaceuticals provides additional pressure to use cheaper generic drugs.
It is interesting to note that during T1 lower allocation labMELD scores incurred higher overall costs due to significantly longer waiting times. This may be surprising as patients with higher labMELD scores would be expected to require more intensive medical inpatient treatment during their waiting time as a consequence of a more progressed liver disease. This study shows that this is obviously more than offset by their shorter waiting times.
As expected, patients with higher pre-transplant lab-MELD scores incurred significantly higher treatment costs in T2 probably as a result of their associated higher morbidity prior to transplantation. Moreover, higher labMELD scores led to higher inpatient costs and to lower outpatient costs. This illustrates that patients with higher labMELD scores incurred less outpatient costs, as these patients spend more time in hospital. This is in congruence to the finding that patients with higher labMELD scores obviously spend most of their treatment time in hospital, especially during T2.
All of these results need to take the national donor liver allocation policy into account, especially when comparing treatment costs between countries without a MELD-based donor organ allocation policies. In this context, it is remarkable that the allocation labMELD scores had no statistically significant influence on costs during follow-up (T3). This is understandable as the labMELD score indicates the severity of liver disease, which has been removed during transplantation. However, patients with HCC or PSC had significantly lower labMELD scores due to the fact that liver allocation for these patients is guided by standard exception MELD points instead of labMELD score points [20] .
Our findings may suggest transplanting patients earlier in the course of their end-stage liver disease with lower labMELD scores as this would probably lower the dominating cost factor caused by inpatient treatments after transplantation. However, such an approach has been shown recently to be associated with lower transplant survival benefits for patients within the first 90 days after transplantation [21] . It comes as no surprise that patients who died early during the first year after transplantation (T2) incurred higher costs compared to surviving patients. This is caused by more frequent prolonged intensive care treatments due to severe complications after transplantation.
During inpatient stays, multiple ERCP interventions were responsible for high costs during each analyzed time frame. During waiting time (T1), the total costs for ERCP interventions are the second most cost-intensive part. In T2, these were one of the most frequent G-DRG-codes and in T3 the ERCP codes were responsible for the biggest part of the costs. These findings point out the severity and intensity of ERCP usage in LTx patients which may point to a need for clinical outcome improvement of biliary reconstruction during transplantation.
During T2, the four G-DRG-codes for transplantation (A01A, A01B, A01C, A18Z) reflect the medical and economic complexity of the intervention per se, as associated costs vary enormously (range: 36 373-323 655€).
In a Finnish cost-effectiveness study, the overall cost per quality-adjusted life year (QALY) in LTx patients was analyzed, with up to 5 years of follow-up [1] . The results showed median annual costs of 141 768€ for the period between listing for transplantation and 1 year after Used to reduce the risk of cardiovascular mortality and morbidity, as well as clinical signs for a heart failure after recent myocardial infarction onset To reduce the risk of cardiovascular mortality and morbidity in adult patients with (chronic) heart failure PegIntron Used for the prophylaxis of the Cytomegalovirus (CMV) disease in CMV-negative adults and children who have received an organ transplant from a CMV-positive donor transplantation. As the waiting time was only 41 days in average, this time frame may be comparable with our time period T2 (median costs 105 566€). The difference in costs between this study and the Finish study might be due to various reasons. For example, the inpatient hospital stay for transplantation is remunerated on the basis of fees (DRGs) in Germany, whereas the inpatient stay and the transplantation procedure are reimbursed separately in the Finnish setting. Furthermore, our Finish colleagues considered costs for organ procurement as well, which was not accounted for in this study. The total cost during the observational period added up to a median of 177 618€ in the Finnish setting, and to a median of 144 424€ within this study. It is interesting to note that the main cost-intensive part in both studies was incurred by the inpatient sector (71-75%).
A meta-analysis of an international systematic review found an average cost of $163 438 for LTx in the United States and of $103 438 for other countries that are members of the Organization for Economic Co-Operation and Development [3] . Within this meta-analysis, one German study was included which calculated average inpatient treatment costs of 49 000€ (range: 18 000-189 000€) on the basis of G-DRGs [9] . Another German study analyzed the influence of organ failure and severe complications, which determined average inpatient cost for the liver transplant procedure at 52 570€ (range: 18 330-397 450€) [10] while in the current study these costs were significantly higher (average costs 111 928€). This may be due to relevant clinical differences in patient populations between treatment centers and the frequency of post-transplant complications compounded by generally increasing costs over time.
A recent study of organ and tissue transplant costs in the United States analyzed billed charges during a time period of 30 days pre-transplant to 180 days post-transplant. For LTx, the total amount of costs was $739 100 [12] . These data provide a valuable orientation to the great variation of the dimension of costs for LTx in different countries. However, these results are difficult to compare to our findings due to substantial differences between the healthcare systems [22] [23] [24] .
This analysis serves as a substructure for a subsequent analysis. We are planning to perform a multivariate analysis of determined cost-driving factors to identify independent factors that drive costs significantly. Such an analysis might provide insight into how these cost drivers may be avoided or reduced.
Some limitations affect the results of this study. No data on medical services at other institutions were analyzed. Our observational period represents only a small part of therapeutic care as patients who receive a transplanted organ require lifelong treatment. The overall lifelong costs of transplantation are therefore probably substantially higher as estimated in this study with limited follow-up times for analysis. Due to the lack of a national transplant registry, we unfortunately cannot state with confidence whether or not the analyzed sample is representative for Germany. It is, however, unlikely that the sample is representative for the Eurotransplant region because of different organ allocation rules in different Eurotransplant member countries.
Conclusion
As interfaces between healthcare sectors contain the hazard of breaks within treatment paths, it is important to support a holistic course of treatment. High requirements for optimized coordination and communication between all involved actors of care implicate a formidable management challenge. Here, the role of the transplant center implies a leading role as our study points out [25, 26] . An integrated and guided exchange of information between decentralized actors is essential to avoid ambiguity and to prevent information loss. Prerequisite for this is the large-scale use of structured information and communication tools, as, for example, an electronic health card or medical record [27] ; especially during aftercare, these points gain in importance as potential interactions of different drugs have to be considered in typically complex medication schemes [28] .
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